Viewing Study NCT06858735


Ignite Creation Date: 2025-12-24 @ 10:37 PM
Ignite Modification Date: 2026-01-02 @ 10:54 AM
Study NCT ID: NCT06858735
Status: RECRUITING
Last Update Posted: 2025-09-08
First Post: 2025-02-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Overview

Official Title: HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Status: RECRUITING
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
Detailed Description: Primary Objective:

To assess the overall survival of patients treated with standard of care systemic therapy with or without liver-directed hypofractionated adaptive RT.

Secondary Objectives:

* Patient-reported quality of life as per the FACT-Hep inventory
* Progression-free survival
* Cause of death

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
NCI-2025-01520 OTHER NCI-CTRP Clinical Trials Registry View